Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate

Criteria

Inclusion Criteria:

• A current clinical diagnosis of Chronic Obstructive Pulmonary Disease

• Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years

• A smoking history of at least 10 pack years

Exclusion Criteria:

• History and/or current clinical diagnosis of asthma

• History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis